Company Encyclopedia
View More
name
RAINMED-B
02297.HK
Rainmed Medical Limited operates as a vascular interventional surgical robotics company in China and internationally. It engages in the research and development, manufacturing, and commercialization of medical instrument related to coronary angiography-derived fractional flow reserve (caFFR) systems and coronary angiography-derived index of microvascular resistance (caIMR) systems. The company also offers caFFR systems comprising FlashAngio caFFR System and FlashPressure caFFR pressure transducer for a less-invasive physiological assessment of coronary artery ischemia severity based on coronary angiography images; and caIMR System, including FlashAngio caIMR System and FlashPressure caIMR pressure transducer, which is a less-invasive index of microcirculatory resistance measurement product for the treatment of microcirculatory lesions. Rainmed Medical Limited was founded in 2014 and is headquartered in Suzhou, China.
132.45 B
02297.HKMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking26/26
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-23.59%E
    • Profit Margin-445.27%E
    • Gross Margin49.18%B
  • Growth ScoreE
    • Revenue YoY-52.94%E
    • Net Profit YoY5.29%C
    • Total Assets YoY-14.51%E
    • Net Assets YoY-13.61%E
  • Cash ScoreE
    • Cash Flow Margin-22.46%D
    • OCF YoY-52.94%E
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreA
    • Gearing Ratio19.23%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Performance" RAINMED's half-year loss narrowed to 32.17 million yuan

    RAINMED-B announced its interim results for the period ending June this year, with a revenue of RMB 10.4 million, a year-on-year decrease of 61.3%. The loss narrowed to RMB 32.169 million, compared to a loss of RMB 41.646 million in the same period last year; the loss per share was RMB 0.02. No dividend was declared

    AASTOCKS·
    HK
    02297
    -1.75%
    AASTOCKS·
    HK
    02297
    -1.75%

    RAINMED-B released its interim results, with a loss attributable to shareholders of 32.2 million yuan, a year-on-year narrowing of 22.6%

    According to the Zhitong Finance APP, RAINMED-B announced its performance for the six months ending June 30, 2025. The group achieved revenue of 10.4 million yuan, a year-on-year decrease of 61.3%; the loss attributable to shareholders was 32.2 million yuan, a year-on-year narrowing of 22.6%; the basic loss per share was 0.02 yuan

    Zhitong·
    HK
    02297
    -1.75%
    Zhitong·
    HK
    02297
    -1.75%

    Shenzhen Tongchuang Weiye Asset Management Co., Ltd. reduced its holdings of RAINMED-B by 13 million shares at a price of HKD 0.3448 per share

    According to the latest information from the Hong Kong Stock Exchange, on August 15, Shenzhen Tongchuang Weiye Asset Management Co., Ltd. reduced its holdings of RAINMED-B by 13 million shares, at a price of HKD 0.3448 per share, totaling HKD 4.4824 million. After the reduction, the latest number of shares held is 67.921 million, with a latest holding ratio of 4.85%. This transaction involves other related parties: Shenzhen Tongchuang Weiye Venture Capital Co., Ltd. and Huang Li

    Zhitong·
    HK
    02297
    -1.75%
    Zhitong·
    HK
    02297
    -1.75%

    Co-CEO Lv Yonghui reduced his holdings of RAINMED-B by 5 million shares at a price of approximately HKD 0.34 per share

    According to the latest information from the Hong Kong Stock Exchange, on August 5th, Co-CEO Lu Yonghui reduced his holdings of RAINMED-B by 5 million shares, at a price of HKD 0.342 per share, totaling HKD 1.71 million. After the reduction, the latest number of shares held is 25.034 million, with a latest holding ratio of 1.79%

    Zhitong·
    HK
    02297
    -1.75%
    Zhitong·
    HK
    02297
    -1.75%

    Lü Yonghui reduced his holdings of RAINMED-B by 795,000 shares at a price of approximately HKD 0.37 per share

    According to the latest information from the Hong Kong Stock Exchange, on August 1st, Lyu Yonghui reduced his holdings of RAINMED-B by 795,000 shares, at a price of HKD 0.3711 per share, totaling approximately HKD 295,000. After the reduction, the latest number of shares held is 31.292 million, with a latest holding ratio of 2.23%

    Zhitong·
    HK
    02297
    -1.75%
    Zhitong·
    HK
    02297
    -1.75%
    © 2025 Longbridge｜Disclaimer